期刊
MICROORGANISMS
卷 9, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/microorganisms9081744
关键词
COVID-19; SARS-CoV-2; pseudovirus; variants of concern; neutralizing antibodies; PBNA; lentiviral vector; MLV vector; spike; neutralization assay; antibody
类别
资金
- National Institute of Allergy and Infectious Diseases (NIAID) [15891.08.01]
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272201700029I, 75N93020F00001]
SARS-CoV-2 genetic variants may reduce the neutralization efficiency of convalescent and post-vaccination sera, raising concerns about increased disease transmissibility and severity. Neutralizing antibody levels are a reliable indicator of vaccine protection, but current detection methods are time-consuming. The development of a BSL-2 pseudovirus-based neutralization assay offers a more convenient and cost-effective alternative.
SARS-CoV-2 genetic variants are emerging around the globe. Unfortunately, several SARS-CoV-2 variants, especially variants of concern (VOCs), are less susceptible to neutralization by the convalescent and post-vaccination sera, raising concerns of increased disease transmissibility and severity. Recent data suggests that SARS-CoV-2 neutralizing antibody levels are a reliable correlate of vaccine-mediated protection. However, currently used BSL3-based virus micro-neutralization (MN) assays are more laborious, time-consuming, and expensive, underscoring the need for BSL2-based, cost-effective neutralization assays against SARS-CoV-2 variants. In light of this unmet need, we have developed a BSL-2 pseudovirus-based neutralization assay (PBNA) in cells expressing the human angiotensin-converting enzyme-2 (hACE2) receptor for SARS-CoV-2. The assay is reproducible (R-2 = 0.96), demonstrates a good dynamic range and high sensitivity. Our data suggest that the biological Anti-SARS-CoV-2 research reagents such as NIBSC 20/130 show lower neutralization against B.1.351 SA (South Africa) and B.1.1.7 UK (United Kingdom) VOC, whereas a commercially available monoclonal antibody MM43 retains activity against both these variants. SARS-CoV-2 spike PBNAs for VOCs would be useful tools to measure the neutralization ability of candidate vaccines in both preclinical models and clinical trials and would further help develop effective prophylactic countermeasures against emerging neutralization escape phenotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据